论文部分内容阅读
目的观察MTA1,ER在乳腺癌中的表达,探讨两者与乳腺癌侵袭能力的相关性。方法应用原位核酸分子杂交和免疫组织化学分别检测正常乳腺组织、癌前病变组织及乳腺癌组织中MTA1,ER的表达;并以Spearman等级相关分析它们的相关性。结果在正常乳腺组织、癌前病变组织、乳腺癌组织中,原位杂交对MTA1,ER的阳性检出率高于免疫组化,原位杂交检测中MTA1 mRNA的表达率分别为12.2%,33.3%,81.1%;免疫组化检测中MTA1的表达率分别为11.1%,31.1%,72.2%;原位杂交检测中ER mRNA的表达率分别为83.3%,61.1%,37.8%,免疫组化检测中ER的表达率分别为70.9%,56.7%和35.6%。MTA1在ER阴性组中的阳性表达率为86.2%,高于阳性组中的46.9%。结论原位杂交和免疫组化联合检测增加MTA1,ER基因的检出率;随疾病的进展和肿瘤分化程度的降低,MTA1表达逐渐增强,ER表达逐渐减弱,甚至丧失。MTA1与ER表达呈负相关(r=-0.466,P<0.01)。提示MTA1,ER可作为乳腺癌预后及治疗重要的分子标记物。
Objective To observe the expression of MTA1 and ER in breast cancer and to explore their correlation with the invasiveness of breast cancer. Methods In situ hybridization and immunohistochemistry were used to detect the expression of MTA1 and ER in normal breast tissue, precancerous lesions and breast cancer tissues respectively. Their correlations were analyzed by Spearman rank correlation analysis. Results The positive rate of MTA1 and ER in normal breast tissue, precancerous lesions and breast cancer tissues was higher than that of immunohistochemistry by in situ hybridization. The expression rates of MTA1 mRNA in in situ hybridization were 12.2% and 33.3 %, 81.1%. The expression rates of MTA1 in immunohistochemistry were 11.1%, 31.1% and 72.2% respectively. The expression rates of ER mRNA in in situ hybridization were 83.3%, 61.1% and 37.8% The expression rates of ER were 70.9%, 56.7% and 35.6% respectively. The positive rate of MTA1 in ER-negative group was 86.2%, which was higher than 46.9% in the positive group. Conclusions In situ hybridization and immunohistochemistry detection can increase the detection rate of MTA1 and ER genes. With the progress of disease and the decrease of tumor differentiation, the expression of MTA1 gradually increases and the expression of ER decreases or even disappears. MTA1 expression was negatively correlated with ER (r = -0.466, P <0.01). Tip MTA1, ER can be used as an important molecular marker prognosis and treatment of breast cancer.